ETC-1922159

Phase 1Small molecule

EEDDC (Experimental Drug Development Centre), A*STAR Research Entities

ETC-1922159 is one of 14 small molecule programs targeting Advanced Solid Tumours. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumoursActive, not recruiting

Advanced Solid TumoursPhase 1

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Advanced Solid Tumours

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

5 2

Imfinzi

AstraZeneca

Phase 2

3 3

Vizimpro

Pfizer

Phase 2

1 4

Tuoyi

CCoherus Oncology, Inc.

Phase 2

2 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 6

LM-108

LLaNova Medicines Limited

Phase 2

3 7

Ceralasertib

AstraZeneca

Phase 1

2 8

ODM-212

Orion Corporation, Orion Pharma

Phase 2

1 9

LM-168

LLaNova Medicines Limited

Phase 2

1 10

RC88

RRemeGen Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Solid Tumours1 trial

A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Active, not recruiting·EEDDC (Experimental Drug Development Centre), A*STAR Research Entities·Phase 1·NCT02521844·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ETC-1922159. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ETC-1922159 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ETC-1922159. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EDDC (Experimental Drug Development Centre), A*STAR Research Entities company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEDDC (Experimental Drug Development Centre), A*STAR Research Entities

ETC-1922159

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News